Alliance Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas Adult CIRB - Late Phase Emphasis Active Available to Open